�鶹��ý

�鶹��ý & Lardner invites you to our U.S. Health Care Arrangements: Legal, Regulatory, and Business Considerations program in Tel Aviv, Israel.

As the U.S. health care sector continues to grow at a rapid rate, there is a recent government push for health care technologies, which has been identified as essential to U.S. health care delivery systems. The U.S. market presents a tremendous opportunity for Israel-based health care companies, as long as the intricacies of U.S. law are thoroughly understood. This program will equip you and your organization with exciting and innovative practices, case studies, and tools to succeed with navigating critical components of the U.S. legal system and expanding your company’s geographic footprint to offer meaningful integration into the U.S. market.

At this session, participants will discuss:

• Opening Remarks:With the participation from the ACC Forum: Health Care & Pharma headed by Ms. Yifat Philip, General Counsel and Corporate Secretary of Kamada.
• Telehealth: (a) Summarize the current regulatory landscape as it relates to telemedicine; (b) Identify key considerations when using telemedicine, including licensure, medical practice standards, prescribing and reimbursement; and (c) What to expect in 2023.
• FDA Regulatory Considerations for the U.S. Market: Digital Health and Clinical Trials – (a) Determining whether product is regulated as a device; (b) FDA pathways; (c) Clinical trial issues; (d) Compliance issues when contracting with health care providers.
• Payor/Provider Convergence: Convergence in the health care market has blurred lines between payors and providers, opening new paths for all involved. Yet, those paths open up even more potential regulatory issues for two already highly regulated industries, from privacy and security issues to tax and licensing concerns.

We will have a networking reception immediately following the program.

If you have any questions, please reach out to Patrick Brennan at [email protected].